The ethyl acetate extract of Wenxia Changfu Formula inhibits the carcinogenesis of lung adenocarcinoma by regulating PI3K-AKT signaling pathway

Scientific Reports
2023.0

Abstract

Lung adenocarcinoma is the most common type of lung cancer. With a rise in new cases worldwide each year, early diagnosis and treatment are very important. Network pharmacology provides the effective way to evaluate poly-pharmacological effects and anticancer molecular mechanisms of drugs. The aim of the present study was to explore the anti-tumor mechanism of ethyl acetate extract of Wenxia Changfu Formula (WFEA) in lung adenocarcinoma by using analytical chemistry, network pharmacology and molecular biology. A total of 193 compounds were identified from WFEA, mainly including esters, phenols, ketones and alkaloids. Totally, 374 targets were regarded as potential targets of WFEA against lung adenocarcinoma. Interestingly, PI3K-AKT was found to be one of the significantly enriched signaling pathways of targets of WFEA against lung adenocarcinoma. AKT1, MMP3, CASP3 and BCL2 had strong binding effect with compound molecules of WFEA. Some combinations with the best docking binding were identified, including quercetin/oleanolic_acid/emodin/aloe_emodin/catechin-AKT1 and quercetin-MMP3. In lung adenocarcinoma cells, the WFEA inhibited the proliferation, migration and invasion, and promoted the apoptosis. Moreover, the WFEA inhibited the mRNA expression of MMP3 and Bcl-2 and promoted the mRNA expression of Caspase3. In addition, WFEA inhibited the protein phosphorylation of AKT and PI3K. The WFEA had a significant inhibitory effect on lung adenocarcinoma cells, which could inhibit cell proliferation, invasion and metastasis, and induce cell apoptosis. The mechanism of action of WFEA may be involved in the regulation of the PI3K-AKT signaling pathway in the lung adenocarcinoma.

Knowledge Graph

Similar Paper

The ethyl acetate extract of Wenxia Changfu Formula inhibits the carcinogenesis of lung adenocarcinoma by regulating PI3K-AKT signaling pathway
Scientific Reports 2023.0
Fangchinoline exerts antitumour activity by suppressing the EGFR‑PI3K/AKT signalling pathway in colon adenocarcinoma
Oncology Reports 2020.0
3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway
Life Sciences 2021.0
Fangchinoline derivatives inhibits PI3K signaling in vitro and in vivo in non-small cell lung cancer
Bioorganic Chemistry 2023.0
Mechanism of Tetrandrine Against Endometrial Cancer Based on Network Pharmacology
Drug Design, Development and Therapy 2021.0
Oxypalmatine regulates proliferation and apoptosis of breast cancer cells by inhibiting PI3K/AKT signaling and its efficacy against breast cancer organoids
Phytomedicine 2023.0
Integration of UPLC–QE–MS/MS and network pharmacology to investigate the active components and action mechanisms of tea cake extract for treating cough
Biomedical Chromatography 2022.0
Synthesis and in vitro anticancer evaluation of novel flavonoid-based amide derivatives as regulators of the PI3K/AKT signal pathway for TNBC treatment
RSC Medicinal Chemistry 2022.0
Bio-Guided Assay of Ephedra foeminea Forssk Extracts and Anticancer Activities: In Vivo, In Vitro, and In Silico Evaluations
Molecules 2023.0
Potential bioactive compounds and mechanisms of Fibraurea recisa Pierre for the treatment of Alzheimer’s disease analyzed by network pharmacology and molecular docking prediction
Frontiers in Aging Neuroscience 2022.0